At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 173 enrolled
Drug / intervention
ezetimibe (+) simvastatindrug
Likely dose
ezetimibe (+) simvastatin 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients
In Brief
A Phase 4 clinical trial evaluating ezetimibe (+) simvastatin for Hypercholesterolemia. Completed, enrolled 173 participants.
Detailed Summary
The purpose of this study is to determine the safety and tolerability of ezetimibe/simvastatin in patients newly diagnosed with dyslipidemia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypercholesterolemia
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
First PostedApr 2008
Primary CompletionJul 2009
TodayJul 2026
First PostedApr 8, 2008
Enrollment StartAug 1, 2007
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 18.2 years ago
Interventions
ezetimibe (+) simvastatindrug
Vytorin 10/20 (ezetimibe 10 mg /simvastatin20 mg) tablet once daily consecutively for 6 weeks.